Francis Payumo
About
Francis Payumo is a scholar working on Oncology, Immunology and Hepatology.
According to data from OpenAlex, Francis Payumo has authored 21 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Immunology and 7 papers in Hepatology. Recurrent topics in Francis Payumo's work include CAR-T cell therapy research (7 papers), Liver physiology and pathology (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Francis Payumo is often cited by papers focused on CAR-T cell therapy research (7 papers), Liver physiology and pathology (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Francis Payumo collaborates with scholars based in United States, Singapore and South Korea. Francis Payumo's co-authors include Herman H. Vandenburgh, May Han, Michael Del Tatto, Julie Lemaire, J. Jac, Peter Lee, Albert S. Chang, Janet Shansky, Monette Cotreau and Anthony W. Tolcher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Francis Payumo
21 papers receiving 376 citations
Peers
Francis Payumo
Masato Igarashi Japan
Yuya Miyauchi Japan
Sadahiko Kita Japan
Bin Jiang China
Di Tang China
Choongseong Han South Korea
Yuefeng Yang China
Hirofumi Toi Japan
Chengjuan Fan China
Xiong Lei China
Citations per year, relative to Francis Payumo Francis Payumo (= 1×)
peers
Masato Igarashi
Countries citing papers authored by Francis Payumo
Since
Specialization
Citations
This map shows the geographic impact of Francis Payumo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Payumo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Payumo more than expected).
Fields of papers citing papers by Francis Payumo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Francis Payumo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Payumo. The network helps show where Francis Payumo may publish in the future.
Co-authorship network of co-authors of Francis Payumo
This figure shows the co-authorship network connecting the top 25 collaborators of Francis Payumo. A scholar is included among the top collaborators of Francis Payumo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis Payumo. Francis Payumo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Payumo, Francis, Rong Wan, E. Gabriela Chiorean, et al.. (2025). A phase I study of AFNT-211, autologous CD4 + and CD8 + T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 43(16_suppl).
2.
Payumo, Francis, E. Gabriela Chiorean, Zhubin Gahvari, et al.. (2024). AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS8650–TPS8650.
3.
Payumo, Francis, E. Gabriela Chiorean, Zhubin Gahvari, et al.. (2024). Abstract CT076: AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. Cancer Research. 84(7_Supplement). CT076–CT076.
4.
Muñoz, Javier, Ian W. Flinn, Jonathon B. Cohen, et al.. (2023). Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma. Transplantation and Cellular Therapy. 30(2). 241.e1–241.e8.
5.
Gotlib, Jason, Tracy I. George, Michael W. Deininger, et al.. (2021). A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). Blood. 138(Supplement 1). 3636–3636.
6.
Siebenhaar, Frank, Jason Gotlib, Michael W. Deininger, et al.. (2021). A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood. 138(Supplement 1). 3642–3642.
7.
Flinn, Ian W., Jason R. Westin, Jonathon B. Cohen, et al.. (2019). Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1587–1587.
8.
Lim, Wan‐Teck, Myung‐Ju Ahn, Quan‐Sing Ng, et al.. (2018). Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical Pharmacology in Drug Development. 7(5). 532–542.
9.
Flinn, Ian W., Jonathon B. Cohen, Luke P. Akard, et al.. (2018). Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma. Blood. 132(Supplement 1). 2966–2966.
10.
Mok, Tony, Sarayut Lucien Geater, Wu‐Chou Su, et al.. (2016). A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of Thoracic Oncology. 11(10). 1736–1744.
11.
Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2014). Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer. 111(2). 272–280.
12.
Mok, Tony, E.H. Tan, James Chih‐Hsin Yang, et al.. (2014). Efficacy Analysis of Gefitinib +/- Ficlatuzumab in Serum Proteomic Based Subgroups of Patients with Previously Untreated Lung Adenocarcinoma. Annals of Oncology. 25. iv70–iv70.
13.
Sarantopoulos, John, Michael S. Gordon, R. Donald Harvey, et al.. (2014). First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 11113–11113.
14.
Tan, E.H., et al.. (2011). Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.. Journal of Clinical Oncology. 29(15_suppl). 7571–7571.
15.
Mok, Tony, J. Jac, May Han, et al.. (2011). Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.. Journal of Clinical Oncology. 29(15_suppl). TPS213–TPS213.
16.
Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2010). Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2525–2525.
17.
Ramanathan, Ramesh K., Francis Payumo, Kyriakos P. Papadopoulos, et al.. (2009). Abstract A100: A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). A100–A100.
18.
Payumo, Francis, Lee P. Smith, Courtney Powell, et al.. (2002). Tissue Engineering Skeletal Muscle for Orthopaedic Applications. Clinical Orthopaedics and Related Research. 403(403 Suppl). S228–S242.
19.
Roy, T. Dutta, et al.. (2001). An in vivo analysis of bone repair products made by three-dimensional fabrication techniques.
20.
Vandenburgh, Herman H., Michael Del Tatto, Janet Shansky, et al.. (1996). Tissue-Engineered Skeletal Muscle Organoids for Reversible Gene Therapy. Human Gene Therapy. 7(17). 2195–2200.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Masato Igarashi Breakdown of academic impact, for papers by Yuya Miyauchi Breakdown of academic impact, for papers by Sadahiko Kita Breakdown of academic impact, for papers by Bin Jiang Breakdown of academic impact, for papers by Di Tang Breakdown of academic impact, for papers by Choongseong Han Breakdown of academic impact, for papers by Yuefeng Yang Breakdown of academic impact, for papers by Hirofumi Toi Breakdown of academic impact, for papers by Chengjuan Fan Breakdown of academic impact, for papers by Xiong Lei